ORGANIZATION: Agency for Healthcare Research and Quality (funding organization) Thomson Reuters. PROBLEM OR ISSUE ADDRESSED: Hospital administrative data have been used in "cost-effectiveness", "cost-benefi t", and "burden-of-illness" studies because they contain large numbers of cases for specifi c conditions and procedures and because charge information is available. While these data generally contain information on how much the facility charged for the hospital stay, they lack information on the cost to provide care and the amount reimbursed for care. In the past, AHRQ developed a set of hospital-level cost-to-charge ratios to estimate the cost of providing care. Currently, AHRQ is piloting a project to create price-to-charge ratios that will be used in conjunction with charge information collected on hospital discharge records to estimate the "price" of inpatient hospital care. In developing priceto-charge ratios, the term "price" refl ects the amount that hospitals are paid by insurers and consumers based on payer revenue information for each hospital. This is the amount of revenue that hospitals actually receive, net of any discounts negotiated with insurers. These ratios will be linked to the Healthcare Cost and Utilization Project (HCUP) State Inpatient Databases (SID). The HCUP SID fi les contain the universe of inpatient discharge abstracts (including information on charges) in participating States, translated into a uniform format to facilitate multi-State comparisons and analyses. Currently, 40 states participate in HCUP, encompassing about 90 percent of all U.S. community hospital discharges. The impetus for this pilot is the President's and Secretary Leavitt's initiatives to make health care information more transparent to consumers. While the addition of price information will help consumers make more informed choices about hospitalizations for themselves and their families, this information will also be valuable for researchers by providing alternatives to measuring resource use that are better suited for their studies. GOALS: The short-term goals of this project include: • Explore the feasibility of creating prices for common hospital diagnoses. • Release prices at a state-wide level for four broad payer groups (Medicare, Medicaid, Private, and self-pay) and groupings of conditions. • Increase understanding of pricing differences among payers. • Release the data publicly after some internal validation. The long term goals of this project include: • Develop price-to-charge ratios for all hospitals by payer states using modeling techniques. • Link price-to-charge ratios to the HCUP databases, which currently contain charge information and estimate costs. • Validate estimated prices with data sources such as CMS, Market Scan, • Provide states with information on hospital average prices that can be used to populate a Website where consumers can explore pricing for common diagnoses. • Release prices publicly on additional AHRQ databases, including national databases such as the Nationwide Inpatient Sample (NIS) and Kids' Inpatient Database (KID).
PODIUM SESSION II: RESEARCH ON METHODS -Cost & Clinical Outcomes Methods

CO1 EVIDENCE-BASED TIME HORIZON FOR THE INTERVENTIONS IN PHARMACOECONOMIC MODELS
Farahani P Berkshire Medical Center, University of Massachusetts Medical School, Pittsfi eld, MA, USA When the measurement of a long-term outcome is necessary, selecting evidence-based time horizons according to pharmacoepidemiology data is crucial. OBJECTIVE: To illustrate the effect of assumed time horizon for the interventions in pharmacoeconomic models on measured outcomes. METHODS: The benefi t of reducing LDL-C was incorporated into a model to calculate reduction in cardiovascular events and resulted economic outcomes. Data for LDL-C reduction from a head-to-head RCT [Am Heart J 2002; 144:1044-51] ; rosuvastatin (starting 5 mg) versus atorvastatin (starting 10 mg) with up-titration doses were incorporated into the model; and distribution of cardiovascular risk for users [N 100,000, duration fi ve years] in Canadian population [Clin Invest Med 2007; 30:E63-E69] were assumed. To fi nd out the effect of time horizon on economic evaluation of therapeutics, the component of fi ve years was changed to ten years time horizon. RESULTS: Using fi ve years duration of therapy, rosuvastatin and atorvastatin can prevent 9505 and 8702 cardiovascular events (nonfatal MI and stroke), respectively. Reduction in non-fatal MI and stroke can be translated to $252,300,392 (CDN) and $230,980,624 direct cost savings, respectively ($288,871,921 and $158,510,416 total net-benefi t). With ten years assumption for statin therapy, rosuvastatin and atorvastatin can prevent 25948 and 22190 cardiovascular events, respectively. The prevention of cardiovascular events according to the model based on ten years time horizon were calculated 2.73 and 2.55 times higher than the fi ve years based model for rosuvastatin and atorvastatin, respectively. CONCLUSION: This simulation study illustrates the effect of incorporated time horizons in pharmacoeconomic models on the resulted outcomes. Therefore, considering an evidence-based time horizon for the model is essential. For example, in this study Canadian community-based clinical practice data reported a median of approximately fi ve years of statin therapy for the patients. Therefore, a time horizon of fi ve years was assumed to be an evidence-based time horizon for the model.
CO2
METHODS FOR INTERPRETING AND DISPLAYING RESULTS: FROM REGRESSION MODELS: BEYOND BETAS AND ODDS RATIOS
Ganz M Abt Bio-Pharma Solutions, Inc. and Harvard School of Public Health, Lexington, MA, USA OBJECTIVE: To present practical methods for interpreting and displaying results from regression models that mitigate the risk of miscommunication and misinterpretation. METHODS: A series of examples of correct and incorrect ways of presenting results from regression models will be presented from the recently published pharmacoeconomics and outcomes research literature. Methods for computing expected values and predicted probabilities from ordinary least squares (OLS) and logistic regression models will be presented. RESULTS: Computing and presenting expected values and predicted probabilities can, and have in some of the published literature, resulted in less ambiguous and easier to interpret results. CONCLUSION: As pharmacoeconomists, we are called on to the present our results not only to our colleagues, but also to policy-makers and the lay media. Therefore, it is important to make sure results from complicated regression analyses are properly communicated and interpreted. However, coeffi cients from all but the simplest models are often incorrectly interpreted. Odds ratios from logistic regression models are even more likely to be misinterpreted (as risk ratios). Furthermore, simply reporting odds ratios does not convey information about the probability of outcomes occurring for reference group(s). It will be argued that computing and presenting the expected value, E(Y), from an OLS model and the predicted probability, Pr(Y), from a logistic regression can help researchers better "tell a story" and result in less ambiguous presentations of fi ndings. For example, the adjusted expected costs of an intervention can be computed for different doses and for different demographic groups and the predicted probability of medication adherence can also be computed as a function of different combinations of patient demographic characteristics and attitudes.
CO3 ESTIMATING DRUG COSTS IN ECONOMIC EVALUATIONS IN IRELAND AND THE UK: AN ANALYSIS OF PRACTICE AND RESEARCH RECOMMENDATIONS
Hughes DA g 1 , Tilson L 2 , Drummond MF 3 1 Bangor University, Bangor, UK, 2 National Centre for Pharmacoeconomics, Dublin, Ireland, 3 University of York, York, Heslington, UK OBJECTIVES: The cost of the drug of interest, its comparator(s) and concomitant drugs, are important parameters in pharmacoeconomic evaluations. Although general methods guidelines exist, there are no specifi c recommendations on drug cost estimation. The aim of this study was to assess current practice in the reporting and conduct of drug costing in Ireland and the UK, and make recommendations for improving future practice. METHODS: We searched the NHS Economic Evaluation Database for evaluations published in Ireland between [2001] [2002] [2003] [2004] [2005] [2006] . Due to the large number of UK studies, we considered only those published between 2005-2006. To assess the generalisability of our fi ndings we included studies from Denmark, Finland and Norway published between 2001-2006 . This generated 59 studies. Data were extracted on: name(s) of medicine(s), route of administration, source of drug cost, cost
